NCT00327119View on ClinicalTrials.gov

Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2006

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

ABX-EGF (panitumumab)

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY